
According to a cover story in Monday's New York Times, the AIDS drug Viracept, by Roche Pharmaceuticals of Switzerland, was recalled in early June, dramatically disrupting treatment for thousands of patients in poor countries.
Batches of the medicine, distributed since March, have been found to contain ethyl mesylate, an "impurity" proven to cause cancer and, at lower levels, genetic mutations in animals—meaning children and fetuses are susceptible.
The article reports that while the United States, Canada, and Japan distribute versions of Viracept produced by another company, Pfizer, a host of other countries have no alternative to the recalled medicine. Global health officials have said Roche did not adequately inform patients about the risks of Viracept or access to replacement medication.
Some countries, like Panama, offer Viracept replacements for triple its price, while Venezuela has no alternative.
Since 2004, Viracept has been sold in 49 countries, the article reports. The recall affects approximately 45,000 patients, according to a Roche estimate. (The Advocate)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.